

May 26, 2010
Announcement no.

Interim Financial Report for Q1 2010 for the BioPorto Company

Summary of Q1 2010

Revenues in Q1 were the highest so far in one quarter, and good growth was achieved compared to Q1 2009. The development of *the NGAL Test* is completed; the test has been transferred to the production upgrade phase and is expected to be launched, as planned, in early 2011.

- Revenues in Q1 2010 rose by 20% to DKK 3.53 million (DKK 2.95 million). Revenues generated by the Group's NGAL portfolio continue to show high growth (65%), compared to Q1 2009.
- The interim result shows a loss of DKK -3.38 million (DKK -3.61 million) for the first three months of the year.
- The development of the NGAL Test, BioPorto's homogeneous renal injury test, is completed, and the production process will now be upgraded. This work is proceeding according to plan and is expected to be completed in Q3. Already at the launch, the test is expected to be adapted to several of the larger producers' fully automated systems currently in use in hospitals worldwide.
- Preparations for launching the NGAL Test in early 2011 also commenced in Q1. The test will be distributed through national distributors, who deliver homogeneous tests for other producers' systems and through large global diagnostic companies for use on their own systems. In Q3, BioPorto expects to conclude the first distribution agreements with national distributors and is also currently in dialogue for the establishment of delivery agreements with large global diagnostics companies.
- In February, BioPorto received ISO certification to European ISO 13485:2003 and ISO 13485:2003 under CMDCAS (Canada) and, in Q1, BioPorto initiated efforts to incorporate US standards with a view to having the NGAL Test registered with the FDA.

Forecasts for the 2010 fiscal year upheld

- In 2010, BioPorto expects that product sales will continue to grow by around 15-25%, and revenues are expected to be DKK 12.5-14 million, not including income from selling licenses.
- Without licensing income, a net loss of around DKK 14-15 million is expected for 2010.
- In terms of the Group's IP rights to the NGAL measurement method, BioPorto expects to enter into agreements concerning other vendors' use of these for developing and marketing the NGAL Test in assay formats other than homogeneous and expects to achieve licensing income in 2010 in the form of one or more down payments.

About BioPorto

BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company's developments include a test (NGAL) to diagnose and monitor acute kidney injury. Within the Company's focus areas, BioPorto's strategy is to develop new methods that can be patented and achieve a wide use in the diagnosis of various diseases. BioPorto was founded in 2000 and has about 25 employees. The Company's shares are listed on NASDAQ OMX Copenhagen (symbol: BIOPOR).

Key figures

(DKK thousand)	2010 3 months	2009 3 months	2009 12 months
Net revenues	3,531	2,948	11,008
Net income/loss , ordinary operating act. (EBIT)	(3,459)	(3,667)	(16,017)
Income/loss from net financials	(12)	53	63
Net income/loss from ordinary operating activities before tax	(3,471)	(3,613)	(15,954)
Net income/loss for the period	(3,471)	(3,613)	(15,954)
Long-term assets	878	1,128	882
Short-term assets	16,677	14,787	19,336
Total assets	17,555	15,914	20,218
Capital stock	126,398	114,908	126,398
Equity	11,938	11,888	15,411
Long-term liabilities	0	0	0
Short-term liabilities	5,617	4,026	4,807
Total liabilities	17,556	15,914	20,218
Cash generated by operations	(2,889)	(3,067)	(13,287)
Cash generated by investment, net	(75)	(14)	(22)
Of which for investment in property, plant and equipment	(75)	(14)	(15)
Cash generated by financing	0	0	14,746
Total cash flow	(2,964)	(3,081)	1,437
Gross margin ratio	59%	54%	57%
Operating margin	-98%	-124%	-145%
Return on investment	-57%	-59%	-264%
Equity interest (equity ratio)	68.0%	74.7%	76.2%
Return on equity	Negative	Negative	Negative
Average no. of employees	22	21	22
Average no. of shares (1,000)	42,120	38,290	39,245
Earnings per share (EPS) DKK	-0.08	-0.09	-0.41
Equity value per share, closing, DKK	0.28	0.31	0.39
Listed price, closing, DKK	7.35	2.81	7.05

Current situation for Q1 2010

NGAL for human diagnostics

The NGAL Test

After the completion of its development, the NGAL Test (BioPorto's homogeneous renal injury assay) is now in the production upgrade phase, which is proceeding according to plan and is expected to be completed in Q3. Preparations for launching the NGAL Test in early 2011 started in earnest in Q1. Concurrent with dialogue about setting up delivery agreements with major global diagnostics companies, BioPorto is working to adapt and enlarge the network of local and national distributors who can market the NGAL Test so the immunoassay can also be marketed locally. From autumn 2010, the Group will also be initiating a number of sales and marketing activities for the purpose of preparing the market for the launch.

The immunoassay was promoted at three international conferences in Q1 and will be promoted at eight more important international trade fairs and scientific meetings in 2010. The initial results achieved by using the NGAL Test were presented by the Group's development manager during ISICEM, a recognized international intensive-care meeting held in Brussels in March. Being able to use the NGAL Test for clinical studies and to present the results at scientific meetings and international conferences are important milestones for BioPorto.

Human NGAL ELISA kits

The human NGAL ELISA kits also accounted for a large share of total revenue growth in Q1. Compared to the revenues generated in Q1 2009, the human NGAL ELISA kits alone grew by 45%. Interest is increasing in BioPorto's NGAL ELISA kits from a number of markets where fully automated analysis systems are still not very prevalent. With a view to selling the Group's human ELISA kits, an exclusive distribution agreement was entered into in May with the Russian company Diakon Ltd., which specializes in registration and distribution in the clinical diagnostics laboratory segment.

Registration

BioPorto qualified for ISO certification in February 2010 according to ISO 13485:2003 and ISO 13485:2003 under CMDCAS (Canadian Medical Device Conformity Assessment System). In Q1, BioPorto continued its efforts to incorporate US standards with a view to having the NGAL Test registered with the FDA.

Intellectual property rights

In Q1, the NGAL cutoff patent was validated in Europe and in May it was approved for issuance in South Korea. It is now valid in twenty European countries, in addition to New Zealand, Singapore and South Africa where the patent has been issued previously. Patent applications have been submitted in a number of other countries and are either pending or being processed.

In April, the Group received the first processing of its cutoff patent from the US Patent and Trademark Office (USPTO). The initial processing preliminarily rejected the patent. BioPorto's patent advisors from Høiberg A/S and the American advisor state that an initial rejection of a patent application is common in the US and, after a thorough review of the examiner's grounds for rejection, the advisors state that the current objections to the patent are expected to be surmountable, resulting in a forthcoming US patent.

In late 2008, Cincinnati's Children Hospital (CCH) was issued with a European patent covering the use of NGAL as a renal injury marker of ischemic renal injury for urine analysis. As stated in announcement no. 23 of December 12, 2008, it is assessed that the patent will not be able to be used in practice or be commercially utilized. To counter any doubt about the application of CCH's rights, BioPorto submitted an objection to CCH's urine patent in Europe in February 2010. The same patent subsequently received an additional objection from patent lawyer Dr. Ute Kilger of Germany, which substantiates BioPorto's assessment of CCH's urine patent as well as the assumption that a number of diagnostics companies are showing great interest in NGAL, including the intellectual property rights, as a result of the marker's great market potential.

In addition, CCH has submitted a European patent application for the use of NGAL as a renal injury marker for serum measurements. The patent will presumably be approved for issuance in the near future. The

assessment of this patent is the same as for the urine patent, the only difference being that the measurement is made in blood. In the light of this, BioPorto's scientific experts and the Group's patent consultants have performed a thorough assessment of the patent situation, which is overall deemed to strengthen BioPorto's NGAL rights. This is generally due to the fact that BioPorto has been issued with and has validated its cutoff patent in twenty European countries, and because it appears unlikely that it will be possible for CCH's two patents to be used in practice or utilized commercially. BioPorto still believes that an NGAL test for diagnosing renal injury in relevant patients cannot be marketed without the manufacturer having to pay for license access to BioPorto's patent rights.

BioPorto is willing to enter into licensing agreements for NGAL IP rights for assay formats other than homogeneous. However it has still not been possible to enter into acceptable agreements concerning the NGAL Test, although a couple of players have begun to launch an NGAL test. Competitive vendors without a license who violate BioPorto's patent rights could face an injunction and claims for damages.

NGAL for measurements in animals

In addition to the Group's NGAL immunoassay for human use, one of the Group's goals is to be able to offer a complete portfolio of monoclonal antibodies and ELISA kits for detecting NGAL in experimental animals. Efforts to transfer the antibodies to ELISA kits are proceeding according to plan. The forthcoming Pig NGAL ELISA kit has completed its development phase, has been transferred to prototype production and is expected to be launched in the summer of 2010. Efforts to develop a Monkey NGAL ELISA kit are continuing, and this kit is expected to be launched in late 2010.

BioPorto's animal NGAL products saw the greatest growth of any product category in Q1 2010, compared to Q1 2009. In Q1, the animal NGAL products were presented at exhibitions, including the US exhibition "ToxExpo", in collaboration with ALPO Diagnostics, BioPorto's US distributor in the animal NGAL area.

APC-PCI

BioPorto has established contact concerning APC-PCI with important opinion makers in the sepsis area, and clinical studies were launched in Q1 2010 to validate the new sepsis marker. The final goal of the studies is to show APC-PCI's expected predictive value in relation to treating sepsis patients with the medicine Xigris. BioPorto has applied for a patent for this diagnostic method. Sales of APC-PCI kits are still modest, but this area is expected to increase concurrent with the expected validation of the marker. BioPorto is continuing its dialogue with diagnostic companies concerning working together to set up the test in a testing format other than ELISA and concerning access to BioPorto's IP and other technology within the APC-PCI area.

The antibody portfolio

Revenues generated by the antibody portfolio rose by 51% in Q1 2010, compared to Q1 2009, a growth rate which is attributable to a targeted effort to increase the promotion of the portfolio via BioPorto's distributors.

BioPorto launched two new antibodies in early May. One antibody is aimed at the peptide YY and enables measurements of PYY (an important appetite-reducing peptide), which is why it is the object of keen interest by pharmaceutical companies developing medicines for treating obesity. The second antibody is aimed at ficolin-H, a protein that is part of the innate immune system. These new products supplement BioPorto's antibody portfolio within two of the Group's core areas: the diabetes/obesity area and the innate immune system.

Annual General Meeting

Carsten Lønfeldt, Peter Nordkild, Niels T. Foged and Marianne Weile were all re-elected at this year's General Meeting, and the board subsequently elected Carsten Lønfeldt as its chairman.

As a result of the coming into effect of the new Danish Companies Act, the Group's articles of association were modified at the Annual General Meeting, and the occasion was also utilized for modernizing the articles

of association; as part of this process, the terms for electronic communication between the Group and stockholders were included into article 11. It is still possible, however, to receive notice of summoning of the Annual General Meeting by ordinary mail, if the stockholder submits a request for this to the Group.

Discussion and Analysis of the Financial Statements by the Management and Board of Directors

Revenues

In Q1, BioPorto generated total revenues of DKK 3.53 million, equivalent to a 20% increase compared to the same period last year (DKK 2.95 million). Growth is attributable to the continued positive trend in the sales of the Group's NGAL products (+65%) and the effect of a targeted effort to increase the promotion of the Group's antibody portfolio.

Costs and financial result

The gross profit rose by 33% to DKK 2.09 million (DKK 1.57 million). The gross margin rose to 59%, compared to 54% for the same period last year.

In Q1, total operating costs amounted to DKK 6.99 million (DKK 6.62 million), equivalent to a 6% increase over the same period last year. In Q1, BioPorto has defrayed appreciable costs for final development of the NGAL Test and the continuation of patents and patent applications.

As a result of the capital loss incurred, financials yielded a net cost of DKK -12,000 in Q1, (net income DKK 53,000).

The financial result for the first three months amounted to a loss of DKK -3.47 million (DKK -3.61 million). The result conforms to the Group's expectations for developments in 2010.

Equity

At the end of the accounting period, the equity was DKK 11.94 million, compared to DKK 15.41 million at the start of the period. This change is attributable to the result for the quarter.

Cash flow

The Group came out of the first three months of 2010 with a total negative cash flow of DKK 2.96 million, compared to DKK 3.08 million in the same period last year. The liquid resources amounted to DKK 11.38 million at the closing of the quarter.

Planned priority areas in Q2 2010

The following action areas deserve particular mention for the Q2 accounting period:

- The primary task will be the upgrading of the NGAL Test. Dialogue about setting up delivery agreements with large global diagnostics companies will continue, and, concurrent with this, BioPorto will work to adapt and enlarge the network of local and national distributors that can market the NGAL Test, so the immunoassay also will be marketed locally.
- BioPorto continues to focus on licensing negotiations for other immunoassay vendors' access to the Group's IP rights, both to NGAL as a diagnostic marker of acute renal injury and to APC-PCI in the sepsis area.
- The Group will spend time and resources on optimizing and defending its patent rights, especially in the US at present.
- In continuation of the ISO 13485:2003 certification achieved, efforts will be made to incorporate US standards with a view to registering the NGAL Test in the US.

Statements about the future

This Interim Financial Report contains statements regarding forecasts for future developments, including in particular future revenues and net results. Such statements are uncertain and risky as many factors, some of which will be beyond BioPorto's control, may cause actual trends to deviate from the forecasts contained in the interim report.

Financial calendar

<i>Quiet period prior to the interim report begins</i>	<i>august 12, 2010</i>
Interim report – 6 months	august 26, 2010
<i>Quiet period prior to the interim report begins</i>	<i>november 10, 2010</i>
Interim report – 9 months	november 24, 2010

Further details:

Thea Olesen, Managing Director
Christina Tønnesen, Investor Relations
Tel.: +45 4529 0000
E-mail: investor@bioporto.com

Statement by the Management and Board of Directors

On today's date, the board and management have discussed and approved the Interim Financial Report for the period from January 1, 2010 to March 31, 2010 for the BioPorto Group.

The Interim Financial Report, which has not been audited or reviewed by the company's accountants, is presented in accordance with IAS 34, "Interim Financial Reporting", as approved by the European Union and in accordance with other Danish disclosure requirements for the interim reports of listed companies.

In our view, the Interim Financial Report presents a true and fair view of the Group's assets, liabilities and financial position as at March 31, 2010 and of the financial results of the Group's activities and cash flow for the period from January 1, 2010 to March 31, 2010.

It is also our view that the statement by the management includes a true and fair account of the trends in the Group's activities and financial situation, the financial results for the period and the Group's financial position in general, as well as a description of significant risks and elements of uncertainty facing the Group.

Gentofte, May 26, 2010

Executive Management:

Thea Olesen
CEO

Board of Directors:

Carsten Lønfeldt
Chairman

Peter Nordkild

Niels T. Foged

Marianne Weile

Income statement

The BioPorto group

	2010 3 months <u>DKK thousand</u>	2009 3 months <u>DKK thousand</u>
Net Revenues	3,531	2,948
Gross income/loss	2,097	1,585
Gross margin ratio	59%	54%
Earnings before interest (EBIT)	(3,459)	(3,667)
EBIT margin ratio	-98%	-124%
Earnings before tax	(3,471)	(3,613)
Income taxes relating to net loss	<u>0</u>	<u>0</u>
Net income/loss for the period	<u>(3,471)</u>	<u>(3,613)</u>
Net income/loss for the period	(3,471)	(3,613)
Comprehensive income	<u>(3,471)</u>	<u>(3,613)</u>
Earnings per Share (eps)	<u>DKK</u>	<u>DKK</u>
Earnings per share (eps/deps)	<u>-0.08</u>	<u>-0.09</u>

Balance sheet

The BioPorto group

ASSETS	2010 March 31 DKK thousand	2009 Dec. 31 DKK thousand	2009 March 31 DKK thousand
Long-term assets			
Tangible assets			
Other plant, operating equipment and fixtures	647	649	903
Tangible assets	647	649	903
Other long-term assets			
Deposits	231	233	224
Other long-term assets, total	231	233	224
Long-term assets, total	878	882	1,128
Short-term assets			
Inventories	3,345	3,296	3,113
Receivables, sales	1,151	1,166	973
Other receivables	800	530	875
Receivables	5,297	4,992	4,961
Cash resources	11,380	14,344	9,826
Short-term assets, total	16,677	19,336	14,787
ASSETS, TOTAL	17,555	20,218	15,914

Balance sheet

The BioPorto group

	2010 March 31 DKK thousand	2009 Dec. 31 DKK thousand	2009 March 31 DKK thousand
LIABILITIES			
Equity			
Capital stock	126,398	126,398	114,908
Share-based payment	1,985	1,985	1,855
Treasury stock	(44)	(44)	(44)
Retained income/loss	(116,400)	(112,928)	(104,831)
Equity, total	11,938	15,411	11,888
Liabilities			
Short-term liabilities			
Suppliers of goods and services	2,011	1,516	1,264
Other debt	3,606	3,291	2,762
Short-term liabilities, total	5,617	4,807	4,026
Liabilities, total	5,617	4,807	4,026
LIABILITIES, TOTAL	17,555	20,218	15,914

Statement of changes in equity

The BioPorto group

	Capital stock DKK thousand	Treasury stock DKK thousand	Share-based payment DKK thousand	Retained income/loss DKK thousand	Total DKK thousand
Equity, January 1, 2010	126,398	(44)	1,985	(112,928)	15,411
Comprehensive income for the period	0	0	0	(3,471)	(3,471)
Equity March 31, 2010	<u>126,398</u>	<u>(44)</u>	<u>1,985</u>	<u>(116,400)</u>	<u>11,939</u>

	Capital stock DKK thousand	Treasury stock DKK thousand	Share-based payment DKK thousand	Retained income/loss DKK thousand	Total DKK thousand
Equity, January 1, 2009	114,908	(44)	1,855	(101,218)	15,501
Comprehensive income for the period	0	0	0	(3,613)	(3,613)
Equity March 31, 2009	<u>114,908</u>	<u>(44)</u>	<u>1,855</u>	<u>(104,831)</u>	<u>11,888</u>

Cash flow statement

The BioPorto group

	2010 3 months DKK thousand	2009 3 months DKK thousand
Earnings before interest (EBIT)	(3,459)	(3,667)
Adjustment for non-cash operating items:		
Depreciation, amortization, write-downs and impairment	77	91
Cash generated by primary operations before change in working capital	(3,382)	(3,575)
Change in working capital	505	455
Cash generated by primary operations	(2,877)	(3,120)
Interest income, included	11	68
Interest expenses, paid	(23)	(15)
Cash generated by operating activities	(2,889)	(3,067)
Purchase of tangible assets	(75)	(14)
Cash generated by investment activities	(75)	(14)
Cash generated by financing activities	0	0
Cash flow for the period	(2,964)	(3,081)
Cash resources at the beginning of the year	14,344	12,907
Cash resources at the end of the period	11,380	9,826

Specifications

Note 1 Accounting policies

The interim accounts are presented as summarized financial statements in accordance with IAS 34, Interim Financial Reporting, as approved by the EU. The interim financial report is also presented in accordance with additional Danish disclosure requirements for interim financial reports for listed companies. Interim financial statements have not been drawn up for the parent company. The interim financial report is presented in Danish kroner (DKK), which is the functional currency of the parent company.

The accounting policies used in the interim financial report are unchanged compared to the accounting policies used in the Group's 2009 annual report.

Note 2 Segment information

2010	ELISA	MABS	Shared	Total
3 months	DKK thousand	DKK thousand	DKK thousand	DKK thousand
Net revenues	1,336	2,055	140	3,531
Production and distribution costs	(608)	(672)	(153)	(1,433)
Gross income/loss	728	1,383	(13)	2,097
Sales and marketing costs	0	0	(1,076)	(1,076)
Research and development costs	0	0	(2,402)	(2,402)
Administration expenses	0	0	(2,078)	(2,078)
Earnings before interest (EBIT)	728	1,383	(5,569)	(3,459)
Purchase of tangible assets	0	0	75	75
Investment activities, total	0	0	75	75
2009	ELISA	MABS	Shared	Total
3 months	DKK thousand	DKK thousand	DKK thousand	DKK thousand
Net revenues	1,026	1,810	111	2,948
Production and distribution costs	(548)	(673)	(142)	(1,363)
Gross income/loss	478	1,138	(31)	1,585
Sales and marketing costs	0	0	(1,547)	(1,547)
Research and development costs	0	0	(1,830)	(1,830)
Administration expenses	0	0	(1,875)	(1,875)
Earnings before interest (EBIT)	478	1,138	(5,283)	(3,667)
Purchase of tangible assets	0	0	14	14
Investment activities, total	0	0	14	14

Note 2 Segment information, continued

	2010 3 months DKK thousand	2009 3 months DKK thousand
The geographical dispersion of the net revenues is as follows:		
Denmark	24	47
EU Member States	941	1,037
North America	1,905	1,424
Asia	434	275
Other	<u>227</u>	<u>165</u>
Net revenues, total	<u>3,531</u>	<u>2,948</u>
Allocation of net revenues:		
NGAL products	1,036	628
Peptide hormone products	699	913
MBL products	426	541
Other products	<u>1,370</u>	<u>866</u>
Net revenues, total	<u>3,531</u>	<u>2,948</u>